Fri, April 14, 2023
Thu, April 13, 2023
Wed, April 12, 2023
Tue, April 11, 2023
Mon, April 10, 2023

Mani Foroohar Upgraded (ARWR) to Buy and Increased Target to $35 on, Apr 12th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-increased-target-to-35-on-apr-12th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Mani Foroohar of SVB Securities, Upgraded "Arrowhead Pharmaceuticals, Inc." (ARWR) to Buy and Increased Target from $21 to $35 on, Apr 12th, 2023.

Mani has made no other calls on ARWR in the last 4 months.



There are 7 other peers that have a rating on ARWR. Out of the 7 peers that are also analyzing ARWR, 1 agrees with Mani's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • William Pickering of "Bernstein" Initiated at Hold and Held Target at $27 on, Tuesday, March 21st, 2023


These are the ratings of the 6 analyists that currently disagree with Mani


  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, February 10th, 2023
  • Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $60 on, Friday, February 10th, 2023
  • Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, February 8th, 2023
  • Luca Issi of "RBC Capital" Maintained at Buy with Decreased Target to $77 on, Tuesday, February 7th, 2023
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $52 on, Tuesday, February 7th, 2023
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023

Publication Contributing Sources